Myasthenia Gravis Panel 2

The Myasthenia Gravis Panel 2 test contains 1 test with 3 biomarkers.

Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: Anti-striated Muscle Antibody

Acetylcholine Receptor

Acetylcholine Receptor

Acetylcholine Receptor